Clinical Research Program

clinical_research_programThe Clinical Research Program (CRP) is a recently formed clinical research program, incorporating the previous St Vincent’s Hospital’s Clinical Trials Centre, HIV Clinical Trials Unit and Antiretroviral Toxicity Research Group. The aim of the CRP is to provide high quality clinical trials service across the St Vincent’s Campus for the clinical implementation of pharmaceutical and investigator-initiated clinical studies. The CRP has clinical trials expertise in multi-centred, investigator-driven research projects, the major focus of the CRP into the future.

CRP currently has 75 research projects across the following clinical specialties:

HIV infection – treatment and observational cohort studies of antiretroviral therapy, treatment complications (particularly metabolic complications), immunopathogenesis, and vaccines;

Viral Hepatitis - treatment and observational cohort studies in patients with and without HIV infection, including new oral treatments for hepatitis C;

Anal Intraepitheal Neoplasia - observational cohort studies of the relationship between AIN and human papillomavirus in men. The CRP recently joined the US AIDS Malignancy Clinical Trials Consortium and will participate in planned treatment studies;

Palliative Care - randomized trials aimed at controlling symptoms in patients with advanced, terminal disease, having recently joined the Australian Palliative Care Clinical Studies Collaborative.

Cardiology - cardiac device and stent studies in collaboration with cardiologists and cardiothoracic surgeons, including of new prosthetic cardiac valves that can be inserted without surgery.


Neurology
- treatment studies of acute stroke, Alzheimer’s disease and Parkinson’s disease.

Innovation and research leadership continue as central themes for the program. The program continues to grow as an effective advocate and collaborator with established research networks, encompassing public-sector, industry and investigator-initiated research. The program commenced participation in a clinical trial of a new class of antiretroviral drugs for the treatment of HIV-1-infection. This investigator driven study is considering the metabolic abnormalities of HIV treatments.

The program continues with a broad range of novel and interesting research of different clinical strategies encompassing therapeutic vaccines studies, gene technology, immunotherapies and clinical evaluation of promising new drug candidates in Phases 1, 2 and 3 of development. The program is gaining specialisation capacity in undertaking pharmacokinetics sub studies. The program also provides clinical research opportunities for PhD, Master and undergraduate students.